It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group

Biological Psychiatry

Volumn 82, Issue 7, 2017, Pages e51-e59

  Krystal, John H ^a,b,c   Davis, Lori L ^d,e   Neylan, Thomas C ^d,f   A Raskind, Murray ^i,j   Schnurr, Paula P ^k,l   Stein, Murray B ^g,h   Vessicchio, Jennifer ^b,c   Shiner, Brian ^k,l   Gleason, Theresa D ^a   Huang, Grant D ^m,n  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b National Center for PTSD   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^k NATIONAL CENTER FOR PTSD   (United States)

^l DARTMOUTH MEDICAL SCHOOL   (United States)

^m DEPARTMENT OF VETERANS AFFAIRS   (United States)

ⁿ VA Office of Research and Development   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID RECEPTOR AFFECTING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HYPNOTIC SEDATIVE AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OPIATE AGONIST; OREXIN RECEPTOR ANTAGONIST; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN 2 ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

CONSENSUS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LETTER; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLDIER; VETERAN; ANIMAL; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 85018878998     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2017.03.007     Document Type: Letter

References (65)

1. Fang, S.C., Schnurr, P.P., Kulish, A.L., Holowka, D.W., Marx, B.P., Keane, T.M., et al. Psychosocial functioning and health-related quality of life associated with posttraumatic stress disorder in male and female Iraq and Afghanistan war veterans: The VALOR registry. J Womens Health 24 (2015), 1038–1046.
2. Goldberg, J., Magruder, K.M., Forsberg, C.W., Kazis, L.E., Ustun, T.B., Friedman, M.J., et al. The association of PTSD with physical and mental health functioning and disability (VA Cooperative Study #569: the course and consequences of posttraumatic stress disorder in Vietnam-era veteran twins). Qual Life Res 23 (2014), 1579–1591.
3. Sherbourne, C.D., Sullivan, G., Craske, M.G., Roy-Byrne, P., Golinelli, D., Rose, R.D., et al. Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med 40 (2010), 2059–2068.
4. Marmar, C.R., Schlenger, W., Henn-Haase, C., Qian, M., Purchia, E., Li, M., et al. Course of posttraumatic stress disorder 40 years after the Vietnam War: Findings from the National Vietnam Veterans Longitudinal Study. JAMA Psychiatry 72 (2015), 875–881.
5. Nock, M.K., Stein, M.B., Heeringa, S.G., Ursano, R.J., Colpe, L.J., Fullerton, C.S., et al. Prevalence and correlates of suicidal behavior among soldiers: Results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). JAMA Psychiatry 71 (2014), 514–522.
6. Thomas, J.L., Wilk, J.E., Riviere, L.A., McGurk, D., Castro, C.A., Hoge, C.W., Prevalence of mental health problems and functional impairment among active component and National Guard soldiers 3 and 12 months following combat in Iraq. Arch Gen Psychiatry 67 (2010), 614–623.
7. Schnurr, P.P., Lunney, C.A., Bovin, M.J., Marx, B.P., Posttraumatic stress disorder and quality of life: Extension of findings to veterans of the wars in Iraq and Afghanistan. Clin Psychol Rev 29 (2009), 727–735.
8. Kessler, R.C., Sonnega, A., Bromet, E., Hughes, M., Nelson, C.B., Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52 (1995), 1048–1060.
9. Perkonigg, A., Kessler, R.C., Storz, S., Wittchen, H.U., Traumatic events and post-traumatic stress disorder in the community: Prevalence, risk factors and comorbidity. Acta Psychiatr Scand 101 (2000), 46–59.
10. Helzer, J.E., Robins, L.N., McEvoy, L., Post-traumatic stress disorder in the general population. Findings of the epidemiologic catchment area survey. N Engl J Med 317 (1987), 1630–1634.
11. Atwoli, L., Stein, D.J., Koenen, K.C., McLaughlin, K.A., Epidemiology of posttraumatic stress disorder: Prevalence, correlates and consequences. Curr Opin Psychiatry 28 (2015), 307–311.
12. Nemeroff, C.B., Owens, M.J., Pharmacologic differences among the SSRIs: Focus on monoamine transporters and the HPA axis. CNS Spectr 9 (2004), 23–31.
13. Friedman, M.J., Marmar, C.R., Baker, D.G., Sikes, C.R., Farfel, G.M., Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 68 (2007), 711–720.
14. Bowers, M.E., Ressler, K.J., An overview of translationally informed treatments for posttraumatic stress disorder: Animal models of Pavlovian fear conditioning to human clinical trials. Biol Psychiatry 78 (2015), E15–E27.
15. Risbrough, V.B., Glenn, D.E., Baker, D.G., On the road to translation for PTSD treatment: Theoretical and practical considerations of the use of human models of conditioned fear for drug development. Curr Top Behav Neurosci 28 (2016), 173–196.
16. van der Kolk, B., Greenberg, M., Boyd, H., Krystal, J., Inescapable shock, neurotransmitters, and addiction to trauma: Toward a psychobiology of post traumatic stress. Biol Psychiatry 20 (1985), 314–325.
17. Pitman, R.K., Rasmusson, A.M., Koenen, K.C., Shin, L.M., Orr, S.P., Gilbertson, M.W., et al. Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 13 (2012), 769–787.
18. Smoller, J.W., The genetics of stress-related disorders: PTSD, depression, and anxiety disorders. Neuropsychopharmacology 41 (2016), 297–319.
19. Logue, M.W., Amstadter, A.B., Baker, D.G., Duncan, L., Koenen, K.C., Liberzon, I., et al. The Psychiatric Genomics Consortium Posttraumatic Stress Disorder Workgroup: Posttraumatic stress disorder enters the age of large-scale genomic collaboration. Neuropsychopharmacology 40 (2015), 2287–2297.
20. Zannas, A.S., Provencal, N., Binder, E.B., Epigenetics of posttraumatic stress disorder: Current evidence, challenges, and future directions. Biol Psychiatry 78 (2015), 327–335.
21. Flandreau, E.I., Toth, M., Animal models of PTSD: A critical review [published online ahead of print Jan 10]. Curr Top Behav Neurosci., 2017.
22. Licznerski, P., Duric, V., Banasr, M., Alavian, K.N., Ota, K.T., Kang, H.J., et al. Decreased SGK1 expression and function contributes to behavioral deficits induced by traumatic stress. PLoS Biol, 13, 2015, e1002282.
23. Im, J.J., Namgung, E., Choi, Y., Kim, J.Y., Rhie, S.J., Yoon, S., Molecular neuroimaging in posttraumatic stress disorder. Exp Neurobiol 25 (2016), 277–295.
24. O׳Doherty, D.C., Chitty, K.M., Saddiqui, S., Bennett, M.R., Lagopoulos, J., A systematic review and meta-analysis of magnetic resonance imaging measurement of structural volumes in posttraumatic stress disorder. Psychiatry Res 232 (2015), 1–33.
25. Hayes, J.P., Vanelzakker, M.B., Shin, L.M., Emotion and cognition interactions in PTSD: A review of neurocognitive and neuroimaging studies. Front Integr Neurosci, 6, 2012, 89.
26. Davis, M., Ressler, K., Rothbaum, B.O., Richardson, R., Effects of D-cycloserine on extinction: Translation from preclinical to clinical work. Biol Psychiatry 60 (2006), 369–375.
27. Frank, J.B., Kosten, T.R., Giller, E.L. Jr., Dan, E., A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 145 (1988), 1289–1291.
28. Brady, K., Pearlstein, T., Asnis, G.M., Baker, D., Rothbaum, B., Sikes, C.R., et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. JAMA 283 (2000), 1837–1844.
29. Davidson, J.R., Rothbaum, B.O., van der Kolk, B.A., Sikes, C.R., Farfel, G.M., Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58 (2001), 485–492.
30. Tucker, P., Zaninelli, R., Yehuda, R., Ruggiero, L., Dillingham, K., Pitts, C.D., Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62 (2001), 860–868.
31. Marshall, R.D., Beebe, K.L., Oldham, M., Zaninelli, R., Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am J Psychiatry 158 (2001), 1982–1988.
32. Lee, D.J., Schnitzlein, C.W., Wolf, J.P., Vythilingam, M., Rasmusson, A.M., Hoge, C.W., Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments. Depress Anxiety 33 (2016), 792–806.
33. Institute of Medicine of the National Acadmies. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. 2007, The National Academies Press, Washington, DC.
34. Northeast Program Evaluation Center. Prescriptions among Veterans with a PTSD diagnosis—Data abstracted from VA Administrative records, June 2016. 2016, VA Office of Mental Health Operations, Washington, DC.
35. Bernardy, N.C., Lund, B.C., Alexander, B., Friedman, M.J., Prescribing trends in veterans with posttraumatic stress disorder. J Clin Psychiatry 73 (2012), 297–303.
36. Krystal, J.H., Rosenheck, R.A., Cramer, J.A., Vessicchio, J.C., Jones, K.M., Vertrees, J.E., et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial. JAMA 306 (2011), 493–502.
37. Shiner, B., Westgate, C.L, Preliminary analysis of 1-year psychotropic medication receipt among VA patients with new episodes of PTSD care, 2004-2013. Ongoing VA-Funded Research, 2016 (“Improving Care for PTSD” HSR&D CDA11-263).
38. Shiner, B., Westgate, C.L., Bernardy, N.C., Schnurr, P.P., Watts, B.V., Anticonvulsant medication use in veterans with posttraumatic stress disorder. J Clin Psychiatry 78 (2017), e545–e552.
39. Harpaz-Rotem, I., Rosenheck, R.A., Tracing the flow of knowledge: Geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs. Arch Gen Psychiatry 66 (2009), 417–421.
40. Raskind, M.A., Peskind, E.R., Hoff, D.J., Hart, K.L., Holmes, H.A., Warren, D., et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 61 (2007), 928–934.
41. Raskind, M.A., Peterson, K., Williams, T., Hoff, D.J., Hart, K., Holmes, H., et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry 170 (2013), 1003–1010.
42. Kelmendi, B., Adams, T.G., Yarnell, S., Southwick, S., Abdallah, C.G., Krystal, J.H., PTSD: From neurobiology to pharmacological treatments. Eur J Psychotraumatol, 7, 2016, 31858.
43. Davidson, J.R., Brady, K., Mellman, T.A., Stein, M.B., Pollack, M.H., The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 27 (2007), 85–88.
44. Gelpin, E., Bonne, O., Peri, T., Brandes, D., Shalev, A.Y., Treatment of recent trauma survivors with benzodiazepines: A prospective study. J Clin Psychiatry 57 (1996), 390–394.
45. Guina, J., Rossetter, S.R., De, R.B., Nahhas, R.W., Welton, R.S., Benzodiazepines for PTSD: A systematic review and meta-analysis. J Psychiatr Pract 21 (2015), 281–303.
46. Rothbaum, B.O., Price, M., Jovanovic, T., Norrholm, S.D., Gerardi, M., Dunlop, B., et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am J Psychiatry 171 (2014), 640–648.
47. Pollack, M.H., Hoge, E.A., Worthington, J.J., Moshier, S.J., Wechsler, R.S., Brandes, M., et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72 (2011), 892–897.
48. Lund, B.C., Bernardy, N.C., Alexander, B., Friedman, M.J., Declining benzodiazepine use in veterans with posttraumatic stress disorder. J Clin Psychiatry, 2011.
49. Guina, J., Nahhas, R.W., Goldberg, A.J., Farnsworth, S., PTSD symptom severities, interpersonal traumas, and benzodiazepines are associated with substance-related problems in trauma patients. J Clin Med, 5, 2016, E70.
50. Kosten, T.R., Fontana, A., Sernyak, M.J., Rosenheck, R., Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse. J Nerv Ment Dis 188 (2000), 454–459.
51. Bernardy, N.C., Lund, B.C., Alexander, B., Jenkyn, A.B., Schnurr, P.P., Friedman, M.J., Gender differences in prescribing among veterans diagnosed with posttraumatic stress disorder. J Gen Intern Med 28:suppl 2 (2013), S542–S548.
52. Weathers, F.W., Keane, T.M., Davidson, J.R., Clinician-administered PTSD scale: A review of the first ten years of research. Depress Anxiety 13 (2001), 132–156.
53. Raskind, M.A., Peskind, E.R., Kanter, E.D., Petrie, E.C., Radant, A., Thompson, C.E., et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study. Am J Psychiatry 160 (2003), 371–373.
54. van Liempt, S., Vermetten, E., Geuze, E., Westenberg, H.G., Pharmacotherapy for disordered sleep in post-traumatic stress disorder: A systematic review. Int Clin Psychopharmacol 21 (2006), 193–202.
55. Byers, M.G., Allison, K.M., Wendel, C.S., Lee, J.K., Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: An assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol 30 (2010), 225–229.
56. Raskind, M.A., Millard, S.P., Petrie, E.C., Peterson, K., Williams, T., Hoff, D.J., et al. Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin. Biol Psychiatry 80 (2016), 736–742.
57. Davidson, J., Bernik, M., Connor, K.M., Friedman, M.J., Jobson, K.O., Kim, Y., et al. A new treatment algorithm for posttraumatic stress disorder. Pyschiatr Ann 35 (2005), 887–900.
58. Management of Post-Traumatic Stress Working Group. VA/DoD Clinical Practice Guideline for Management of Post-Traumatic Stress Disorder. 2010, Department of Veterans Affairs and Department of Defense, Washington, DC.
59. Petrakis, I.L., Desai, N., Gueorguieva, R., Arias, A., O׳Brien, E., Jane, J.S., et al. Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: A clinical trial. Alcohol Clin Exp Res 40 (2016), 178–186.
60. Gaynes, B.N., Warden, D., Trivedi, M.H., Wisniewski, S.R., Fava, M., Rush, A.J., What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60 (2009), 1439–1445.
61. Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., et al. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials 25 (2004), 119–142.
62. Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D., et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354 (2006), 1243–1252.
63. GSK Clinical Study Register. A randomized, double-blind, placebo-controlled parallel-group, fixed-dose study evaluating the efficacy and safety of the neurokinin-1 receptor antagonist orvepitant (GW823296) in post traumatic stress disorder (PTSD). Protocol summary, 2013 Available at: http://GSK-clinicalstudyregister.com/study/113211. Accessed February 20, 2017.
64. Sullivan, G., Gendreau, J., Gendreau, R.M., Schaberg, A., Daugherty, B., Jividen, H., et al. The AtEase study: A Phase 2 multicenter, randomized clinical trial of the safety and efficacy of TNX-102 SL in the treatment of military-related PTSD. 2016, Poster presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology, December 7, Hollywood, Florida.
65. Back, S.E., McCauley, J.L., Korte, K.J., Gros, D.F., Leavitt, V., Gray, K.M., et al. A double-blind randomized, controlled pilot trial of N-acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry 77 (2016), e1439–e1446.